Replies to post #387147 on Anavex Life Sciences Corp (AVXL)

[markjohn62]

273 did about the same as lecanemab.

Even that is a positive with the good safety profile and likely much less expensive price tag.

[1950jtom]

The numbers were better than Lecanemab, and it has none of the disastrous side-effects. And it's a pill or capsule, not an injectable. Lecanemab will never be in the marketplace. AVXL stands alone.

[imho]

Have you seen the data, or are you going by the PR?

IMHO

[frrol]

Hopefully the dose arm breakout shows dose effect and good tolerability. Looking forward to seeing this and the wtS1 breakout. Watching for the presentation materials.

[Fireman02360]

It did BETTER than lecanemab....in ADAS-Cog, CDR and ADSC.

Why just not admit you were wrong? You and the others, WRONG!

Like I stated last night, the so called "experts" on this board have been wrong since $1.25. They will be wrong @ $50 as well.

-Fireman

[growingpain]

MacFarlane was asked about the pooling after his presentation. He said that Anavex received the data two weeks ago and they did not have the time to compare the individual treatment groups to the placebo. Notably, he also said that he received the slides one hour before his presentation. I believe him as he did not seem well prepared at all.

[dennisdave]

Im 75% certain Anavex will need an additional trial to iron out the already mentioned insurmountable. Not for nothing, Anavex mentions counseling the FDA for follow-up advice.

I do expect a run in the SP but then after reality sets in probably to walk back again. JMHO

Btw I think its outrageous Anavex has called it met endpoints when at the same time they have made these incredibly stupid mathematic errors